Advertisement
ALC vs DHR
Which Stock Would AI Choose? Alcon Inc. (ALC) vs. Danaher Corporation (DHR) Stock Comparison
Key Takeaways
- Alcon Inc. (ALC) demonstrates greater recent stability, with a 1-month decline of 0.72% compared to Danaher Corporation's (DHR) 8.83% drop, amid broader healthcare sector pressures.
- ALC's market capitalization stands at approximately $37 billion, significantly smaller than DHR's $124 billion, reflecting differing scales in the medtech space.
- Both stocks trade at elevated P/E ratios (price-to-earnings ratios)—ALC at 37.4 and DHR at 33.9—indicating growth expectations despite year-to-date declines of 6% and 23%, respectively.
- Recent catalysts include ALC's launch of the Clareon TruPlus intraocular lens and DHR's $10 billion Masimo acquisition, influencing short-term sentiment.
- Analyst price targets point to potential upside: $94 for ALC and $250 for DHR, with moderate buy consensus for both.
Introduction
Alcon Inc. (ALC) and Danaher Corporation (DHR) represent key players in the medical technology sector, with ALC specializing in eye care products and DHR offering a diversified portfolio in life sciences and diagnostics. This comparison is particularly relevant for investors and traders navigating healthcare market volatility, where sector-specific innovations and macroeconomic pressures shape performance. By examining recent trends, financial metrics, and strategic developments, readers can assess relative positioning in a landscape marked by acquisition activity and product launches. Understanding these dynamics aids in evaluating stock comparison opportunities amid shifting market sentiment.
ALC Overview and Recent Performance
Alcon Inc. (ALC) is a leading global provider of eye care products, including surgical equipment, pharmaceutical eye drops, and vision care solutions. The company operates in a niche market driven by aging populations and advancements in ophthalmology. In recent market activity, ALC shares have traded within a 52-week range of $71.55 to $98.56, reflecting resilience despite broader healthcare headwinds. Year-to-date performance shows a modest decline of around 6%, with a 1-month drop of 0.72% and 3-month decrease of 6.66%. Key influences include the launch of the Clareon TruPlus intraocular lens (IOL) at recent conferences, bolstering surgical franchise growth, alongside quarterly revenue increases of about 7-8% and an upcoming earnings report. Positive analyst updates and a dividend declaration have supported sentiment, though tariff concerns and competitive pressures temper gains.
DHR Overview and Recent Performance
Danaher Corporation (DHR) is a diversified conglomerate focused on life sciences, diagnostics, and environmental applied solutions, leveraging a continuous improvement system and M&A (mergers and acquisitions) strategy for growth. Recent weeks have seen heightened volatility, with shares near the 52-week low of $174.60 after peaking at $242.80. Year-to-date returns stand at -23%, with sharper declines of 8.83% over one month and 21.61% over three months. Sentiment has been pressured by a $908 million earnings charge, a $172.5 million shareholder lawsuit settlement, and debt issuance for the $10 billion Masimo acquisition. Despite these, core revenue growth around 4% and analyst overweight ratings provide a foundation, with focus on integration and future profitability.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available models that trade thousands of tickers across various assets. These bots employ diverse strategies, including trend trading, swing trading, and take-profit/stop-loss corridors, with timeframes from 5 minutes to daily. Performance stats are compelling: annualized returns range from 23.53% to 163.10% (average ~65.5%), win rates from 51.30% to 88.33% (average ~60.5%), and profit factors up to 11.70. Focused on high-momentum sectors like semiconductors (e.g., NVDA, AMD) and tech, they incorporate risk management via virtual or signal agents suitable for copy trading. Traders can explore these to identify bots aligning with current market conditions and their risk tolerance.
Head-to-Head Comparison
ALC and DHR both anchor in healthcare but diverge in business models: ALC as a pure-play eye care specialist benefits from targeted innovation, while DHR's conglomerate structure relies on M&A and operational efficiencies across life sciences. Growth drivers contrast with ALC's steady 5-8% revenue expansion versus DHR's mixed results amid integration challenges. Recent momentum favors ALC with shallower pullbacks, though DHR offers scale advantages. Risk factors include execution risks for DHR's acquisitions and competition for ALC. Sector exposure is similar, but market sentiment leans toward ALC's stability in recent trading.
Tickeron AI Verdict
Tickeron’s AI analysis currently favors ALC over DHR due to superior relative momentum, with less pronounced recent declines and consistent product-driven catalysts enhancing trend stability. While DHR holds long-term diversification strengths, near-term positioning gives ALC a probabilistic edge in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALC is a StrongBuy and DHR is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALC’s FA Score shows that 1 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s).
- ALC’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALC’s TA Score shows that 5 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s).
- ALC’s TA Score: 5 bullish, 3 bearish.
- DHR’s TA Score: 4 bullish, 6 bearish.
Price Growth
ALC (@Pharmaceuticals: Other) experienced а +0.06% price change this week, while DHR (@Medical Specialties) price change was -2.28% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.49%. For the same industry, the average monthly price growth was +1.13%, and the average quarterly price growth was -15.35%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
ALC is expected to report earnings on Aug 10, 2026.
DHR is expected to report earnings on Jul 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.49% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ALC | DHR | ALC / DHR | |
| Capitalization | 32.6B | 127B | 26% |
| EBITDA | 2.54B | 7.08B | 36% |
| Gain YTD | -15.176 | -21.159 | 72% |
| P/E Ratio | 40.03 | 34.90 | 115% |
| Revenue | 10.6B | 24.8B | 43% |
| Total Cash | 1.66B | 5.7B | 29% |
| Total Debt | 5.25B | 18.5B | 28% |
ALC | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 89 | 81 | |
PRICE GROWTH RATING 1..100 | 61 | 58 | |
P/E GROWTH RATING 1..100 | 50 | 65 | |
SEASONALITY SCORE 1..100 | 50 | 26 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is in the same range as ALC (18) in the Hospital Or Nursing Management industry. This means that DHR’s stock grew similarly to ALC’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ALC (100) in the Hospital Or Nursing Management industry. This means that DHR’s stock grew similarly to ALC’s over the last 12 months.
DHR's SMR Rating (81) in the Medical Specialties industry is in the same range as ALC (89) in the Hospital Or Nursing Management industry. This means that DHR’s stock grew similarly to ALC’s over the last 12 months.
DHR's Price Growth Rating (58) in the Medical Specialties industry is in the same range as ALC (61) in the Hospital Or Nursing Management industry. This means that DHR’s stock grew similarly to ALC’s over the last 12 months.
ALC's P/E Growth Rating (50) in the Hospital Or Nursing Management industry is in the same range as DHR (65) in the Medical Specialties industry. This means that ALC’s stock grew similarly to DHR’s over the last 12 months.
| ALC | DHR | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 40% | 3 days ago 58% |
| Stochastic ODDS (%) | 3 days ago 55% | 3 days ago 63% |
| Momentum ODDS (%) | 3 days ago 63% | 3 days ago 57% |
| MACD ODDS (%) | 3 days ago 64% | 3 days ago 46% |
| TrendWeek ODDS (%) | 3 days ago 59% | 3 days ago 64% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 54% |
| Advances ODDS (%) | 3 days ago 58% | 11 days ago 54% |
| Declines ODDS (%) | 12 days ago 56% | 3 days ago 61% |
| BollingerBands ODDS (%) | 7 days ago 58% | 3 days ago 53% |
| Aroon ODDS (%) | 3 days ago 51% | 3 days ago 62% |
Advertisement
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.